ELOXX PHARMACEUTICALS, INC. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Issuances
ELOXX PHARMACEUTICALS, INC. (ELOX) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Issuances of $1.10 million for the 12-month period ending 2017-06-30, per its 10-K filed 2017-10-13.
Discontinued › Notes › Fair Value Measures and Disclosures › Fair Value Disclosures › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetIssues · last filed 2017-10-13
- ELOXX PHARMACEUTICALS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, issuances for the quarter ending 2017-06-30 was $512.35K.
- ELOXX PHARMACEUTICALS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, issuances for fiscal 2017 was $1.10M.
- ELOXX PHARMACEUTICALS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, issuances for fiscal 2016 was $0.00.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Issuances 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Issuances 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Issuances 12 month |
|---|---|---|---|
| 2017-06-30 | $512.35K derived: 10-K 12 month − 10-Q 9 month · filed 2017-10-13 | $1.10M 10-K · filed 2017-10-13 | |
| 2017-03-31 | $589.07K 10-Q · filed 2017-05-22 | ||
| 2016-06-30 | $0.00 10-K · filed 2017-10-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Tevogen Inc. (TVGN) | United States | $0.049B |